Men with Low-Risk Prostate Cancer Face Lower All-Cause Mortality vs. Cancer-Free Men
the Cancer Therapy Advisor take:
Men with low-risk prostate cancer (PCa) face lower all-cause mortality compared to PCa-free men due to lower cardiovascular mortality.
Additionally, men with intermediate or high risk face substantial death risk regardless of Charlson comorbidity index (CCI).
These results were part of a recent study published in BJU International which looked at patient data gathered from PCBase Sweden. Mieke van Hemelrijck, PHD, and fellow researchers at King’s College London in the UK observed 57,187 men diagnosed with localized PCa between 1997 to 2009 as well as 114,374 age- and county-matched PCa-free control men.
They found that in men with low-risk PCa, all-cause mortality after 10 years was 18 percent compared to corresponding men without PCa who were at 21 percent, with 31 percent of patients dying from CVD compared to 37 percent, respectively.
In low-risk men, PCa was the third most common cause of death after cardiovascular disease and other cancers. In men with intermediate and high-risk localized PCa, their disease was the most common cause of death.
Men with low-risk PCa face lower all-cause mortality compared to PCa-free men.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
- Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
- Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models